Head to Head Analysis: Arbutus Biopharma (NASDAQ:ABUS) and YD Bio (NASDAQ:YDES)

YD Bio (NASDAQ:YDES) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Insider & Institutional Ownership

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares YD Bio and Arbutus Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	$596,817.00	300.09	N/A	N/A	N/A
Arbutus Biopharma	$14.08 million	64.47	-$33.50 million	$0.83	5.54

YD Bio has higher earnings, but lower revenue than Arbutus Biopharma.

Profitability

This table compares YD Bio and Arbutus Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Arbutus Biopharma	83.95%	129.32%	112.24%

Analyst Ratings

This is a breakdown of recent recommendations for YD Bio and Arbutus Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1	0	0	0	1.00
Arbutus Biopharma	1	0	1	0	2.00

Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 8.81%. Given Arbutus Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Arbutus Biopharma is more favorable than YD Bio.

Summary

Arbutus Biopharma beats YD Bio on 9 of the 10 factors compared between the two stocks.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.